Matrix Global Advisors
  • Home
  • About
  • News
  • Reports
  • Contact
  • Follow
  • Follow
A Drug with Two Prices

A Drug with Two Prices

Apr 27, 2023 | Commentary

After 20 years, the monopoly for Abbvie’s Humira (adalimumab) has ended with the recent entry of Amgen’s biosimilar Amjevita. However, Amgen’s dual pricing strategy for its product has been raising some eyebrows.

  • Analysis (50)
  • Books (3)
  • Commentary (15)
  • Events (21)
  • Interviews (59)
  • News (55)
  • Op-Eds (96)
  • Press Releases (4)
  • Testimony (21)
  • effects of 304B
    The 340B Program’s Negative Impact on Pharmaceutical InnovationJune 5, 2025
  • a conversation on tax reform
    A Conversation with House Ways and Means Committee Chairman Jason Smith on Tax ReformMarch 5, 2025
  • US Biosimilars Market
    New MGA Paper Identifies Barriers to US Biosimilar Success in the Second DecadeMarch 5, 2025
  • Congress on the Brink of Disrupting the PBM Market
    Congress on the Brink of Disrupting the PBM MarketJanuary 27, 2025
  • Raising the Salt Cap Would Increase Tax Complexity
    Raising the Salt Cap Would Increase Tax ComplexityJanuary 13, 2025
  • Economics of “Delinking” Are Still Not Good
    Economics of “Delinking” Are Still Not GoodDecember 13, 2024
  • Child Tax Credit Tradeoffs
    The Child Tax Credit: Tradeoffs and PreferencesOctober 30, 2024
  • Oregon’s Measure 118 Turnover Tax
    Oregon’s Measure 118: The Turnover Tax Is the WorstOctober 29, 2024
  • Dueling Child Tax Credit Proposals
    Dueling Child Tax Credit Proposals: Harris vs. VanceOctober 21, 2024
  • Deduction for Auto Loan Interest
    Trump Proposes Bringing Back the Deduction for Auto Loan InterestOctober 16, 2024
© Copyright 2022 Matrix Global Advisors | Design By DreamBig Creative
MGA
  • Home
  • About
  • News
  • Reports
  • Contact